Technology appraisal (TA) Date of TA Release Adherence of local formulary to NICE Titles are hyperlinks to full guidance (N.B. if exact date is not specified Yes N/A Date of local Time to implement Notes (e.g. Additional stipulations, rationale, in NICE documentation, the last day of the month published will (mark 'x' if (mark 'x' if decision (days) method of making available) be employed) applicable) applicable) (DD/MM/YY)

2019-20 Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated 04/03/2020 X 04/03/2020 0 appraisal) [TA625]

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [TA624] 19/02/2020 X 06/04/2020 47

Patiromer for treating hyperkalaemia [TA623] 13/02/2020 X 16/02/2020 3

Sotagliflozin with insulin for treating type 1 diabetes [TA622] 12/02/2020 X 16/02/2020 4

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer [TA621] 22/01/2020 X 06/04/2020 75

Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or 15/01/2020 X 06/04/2020 82 peritoneal cancer [TA620]

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced 15/01/2020 X 06/04/2020 82 breast cancer [TA619]

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non- 15/01/2020 X 15/01/2020 0 small-cell lung cancer (terminated appraisal) [TA618]

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a 08/01/2020 06/04/2020 89 planned invasive procedure [TA617]

Cladribine for treating relapsing–remitting multiple sclerosis [TA616] 19/12/2019 X 21/01/2020 33

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome 18/12/2019 X 21/01/2020 34 [TA615]

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome [TA614] 18/12/2019 X 21/01/2020 34

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in 20/11/2019 X 21/11/2019 1 phakic eyes after an inadequate response to previous therapy [TA613]

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early 20/11/2019 X 21/01/2020 62 stage breast cancer after adjuvant trastuzumab [TA612]

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or 13/11/2019 X 21/01/2020 69 peritoneal cancer [TA611]

Pentosan polysulfate sodium for treating bladder pain syndrome [TA610] 13/11/2019 X 21/11/2019 8 Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated 30/10/2019 X 30/10/2019 0 appraisal) [TA609]

Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) 30/10/2019 X 30/10/2019 0 [TA608]

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral 17/10/2019 X 21/11/2019 35 artery disease [TA607]

Lanadelumab for preventing recurrent attacks of hereditary angioedema [TA606] 16/10/2019 X 21/01/2020 97

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea [TA605] 09/10/2019 X 17/10/2019 8

Idelalisib for treating refractory follicular lymphoma [TA604] 02/10/2019 X 02/10/2019 0 Not recommended for use by NICE

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma 25/09/2019 X 25/09/2019 0 (terminated appraisal) [TA603]

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple 25/09/2019 X 25/09/2019 0 myeloma (terminated appraisal) [TA602]

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) 25/09/2019 X 25/09/2019 0 [TA601]

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small- 11/09/2019 X 15/10/2019 34 cell lung cancer [TA600]

Sodium zirconium cyclosilicate for treating hyperkalaemia [TA599] 04/09/2019 X 19/09/2019 15

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian 28/08/2019 X 15/10/2019 48 tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598]

Dapagliflozin with insulin for treating type 1 diabetes [TA597] 28/08/2019 X 19/09/2019 22

Risankizumab for treating moderate to severe plaque psoriasis [TA596] 21/08/2019 X 19/09/2019 29

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer [TA595] 14/08/2019 X 15/10/2019 62

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) 14/08/2019 X 14/08/2019 0 [TA594]

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced 14/08/2019 X 15/10/2019 62 breast cancer [TA593]

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma 07/08/2019 X 15/10/2019 69 [TA592]

Letermovir for preventing cytomegalovirus disease after a stem cell transplant [TA591] 31/07/2019 X 15/10/2019 76 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis [TA590] 31/07/2019 X 15/08/2019 15

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual 24/07/2019 X 15/10/2019 83 disease activity [TA589]

Nusinersen for treating spinal muscular atrophy [TA588] 24/07/2019 X 15/10/2019 83

Lenalidomide plus dexamethasone for previously untreated multiple myeloma [TA587] 26/06/2019 X 16/07/2019 20

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib 26/06/2019 X 16/07/2019 20 [TA586]

Ocrelizumab for treating primary progressive multiple sclerosis [TA585] 12/06/2019 X 16/07/2019 34

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer 05/06/2019 X 16/07/2019 41 [TA584]

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes 05/06/2019 X 20/06/2019 15 [TA583]

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) 24/05/2019 X 24/05/2019 0 [TA582]

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma [TA581] 15/05/2019 X 16/07/2019 62

Enzalutamide for hormone-relapsed non-metastatic prostate cancer [TA580] 15/05/2019 X 15/05/2019 0 Not recommended for use by NICE

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced 08/05/2019 X 16/07/2019 69 breast cancer after endocrine therapy [TA579]

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after 01/05/2019 X 16/07/2019 76 platinum-based chemoradiation [TA578]

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma [TA577] 24/04/2019 X 16/07/2019 83

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) [TA576] 17/04/2019 X 17/04/2019 0

Tildrakizumab for treating moderate to severe plaque psoriasis [TA575] 17/04/2019 X 16/05/2019 29

Certolizumab pegol for treating moderate to severe plaque psoriasis [TA574] 17/04/2019 X 16/05/2019 29

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma 10/04/2019 X 16/07/2019 97 [TA573] _ Average % "Yes" % "N/A" implement time (days) Adherence statistics for 2019-20 81.0% 19.0% 37